I have taken a long position in INO here.
INO is in human trials for covid-19 vaccine with safety results expected in late June. Multiple possible catalyst including further funding. NVAX just received $388 million from CEPI and with INO being one of the few in human trials for covid-19 vaccine already, further funding for INO is likely as well.
This is not a recommendation to buy.
This is not financial advice.
INO is in human trials for covid-19 vaccine with safety results expected in late June. Multiple possible catalyst including further funding. NVAX just received $388 million from CEPI and with INO being one of the few in human trials for covid-19 vaccine already, further funding for INO is likely as well.
This is not a recommendation to buy.
This is not financial advice.
Commentaire:
Not turning out like I planned so far. Still on high watch. Only a matter of time imo.
Trade fermée: cible de profit atteinte:
Boomshakalaka